Replimune Group (REPL) Set to Announce Earnings on Wednesday

Replimune Group (NASDAQ:REPL) is projected to post its Q2 2027 results before the market opens on Wednesday, October 28th. Analysts expect Replimune Group to announce earnings of ($0.7840) per share and revenue of $1.00 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, analysts expect Replimune Group to post ($2.82) EPS for the current fiscal year and ($2.04) EPS for the next fiscal year.

Replimune Group Price Performance

Shares of REPL opened at $11.46 on Monday. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average price of $13.53 and a two-hundred day moving average price of $9.88. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -3.64 and a beta of 0.93. Replimune Group has a 12 month low of $1.50 and a 12 month high of $16.33.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on REPL. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Tuesday, June 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. JPMorgan Chase & Co. boosted their price target on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, August 26th. Finally, Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

Insider Activity

In related news, CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the transaction, the chief accounting officer directly owned 99,425 shares of the company’s stock, valued at $1,289,542.25. This trade represents a 7.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of Replimune Group stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 79,124 shares of company stock worth $1,038,364. Company insiders own 5.40% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.